Text this: Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals <i>CSF3</i> as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens